Dr. Jing Li was awarded Susan G. Komen Breast Cancer Foundation Fellowship
Dr. Li, a postdoctoral fellow in the Springer lab, will test the hypothesis that the conformational ensemble of integrin α5β1 specifies its function, and rational perturbation of its ensemble with conformation-selective antibody or small molecules can convert its role from protumoral to a tumor-inhibiting, and even eradicate dormant breast cancer cells that are resistant to traditional therapies.
Founded in 1953, the Program in Molecular and Cellular Medicine and the Immune Disease Institute (PCMM/IDI) is a non-profit research institution in Boston, MA, recognized worldwide for its discoveries that increase the body's ability to fight disease and to heal. With the aim of increasing collaborations and scientific synergies, Immune Disease Institute and Children’s Hospital Boston have entered into an affiliation whereby IDI joins seven other interdisciplinary programs as the Program in Cellular and Molecular Medicine. PCMM/IDI is also academically affiliated with Harvard Medical School, and its investigators hold appointments in departments of the medical school.
The breakthroughs of PCMM/IDI scientists are greatly increasing our understanding of the influence of immune defense and inflammation on biomedical discovery, healthcare, and disease management. Visit About Us to learn more.